53 related articles for article (PubMed ID: 3965161)
1. Preoperative therapy for advanced pelvic malignancy by isolated pelvic perfusion with the balloon-occlusion technique.
Wanebo HJ; Chung MA; Levy AI; Turk PS; Vezeridis MP; Belliveau JF
Ann Surg Oncol; 1996 May; 3(3):295-303. PubMed ID: 8726186
[TBL] [Abstract][Full Text] [Related]
2. Tumour response to chemotherapy in animals that have been treated with the same drugs prior to tumour implantation: a model for studying host effects on apparent drug resistance.
Luk CK; Tannock IF
Br J Cancer; 1988 Aug; 58(2):133-8. PubMed ID: 3166902
[TBL] [Abstract][Full Text] [Related]
3. Schedule-dependency of in vivo modulation of 5-fluorouracil by leucovorin and uridine in murine colon carcinoma.
Nadal JC; van Groeningen CJ; Pinedo HM; Peters GJ
Invest New Drugs; 1989 Jul; 7(2-3):163-72. PubMed ID: 2793368
[TBL] [Abstract][Full Text] [Related]
4. Toxicology and carcinogenesis studies of androstenedione (CAS No. 63-05-8) in F344/N rats and B6C3F1 mice (gavage studies).
Natl Toxicol Program Tech Rep Ser; 2010 Sep; (560):1, 7-31,33-171 passim. PubMed ID: 21037592
[TBL] [Abstract][Full Text] [Related]
5. Decreased host toxicity in vivo during chronic treatment with 5-flourouracil.
Darnowski JW; Sawyer RC; Stolfi RL; Martin DS; Lau-Cam CA
Cancer Chemother Pharmacol; 1985; 14(1):63-9. PubMed ID: 3965161
[TBL] [Abstract][Full Text] [Related]
6. Potentiation of 5-fluorouracil efficacy by the dihydrouracil dehydrogenase inhibitor, 5-benzyloxybenzyluracil.
Naguib FN; Hao SN; el Kouni MH
Cancer Res; 1994 Oct; 54(19):5166-70. PubMed ID: 7923135
[TBL] [Abstract][Full Text] [Related]
7. Protection by testosterone from fluorouracil-induced toxicity without loss of anticancer acitvity against autochthonous murine breast tumors.
Stolfi RL; Sawyer RC; Nayak R; Spiegelman S; Martin DS
Cancer Res; 1980 Aug; 40(8 Pt 1):2730-5. PubMed ID: 7388822
[TBL] [Abstract][Full Text] [Related]
8. Modulation of 5-fluorouracil host-toxicity and chemotherapeutic efficacy against human colon tumors by 5-(Phenylthio)acyclouridine, a uridine phosphorylase inhibitor.
Al Safarjalani ON; Rais R; Shi J; Schinazi RF; Naguib FN; el Kouni MH
Cancer Chemother Pharmacol; 2006 Nov; 58(5):692-8. PubMed ID: 16528530
[TBL] [Abstract][Full Text] [Related]
9. Potent combination therapy for human breast tumors with high doses of 5-fluorouracil: remission and lack of host toxicity.
Al Safarjalani ON; Rais R; Naguib FN; el Kouni MH
Cancer Chemother Pharmacol; 2012 Jun; 69(6):1449-55. PubMed ID: 22373605
[TBL] [Abstract][Full Text] [Related]
10. Failure of L-histidinol to improve the therapeutic efficiency of 5-fluorouracil against murine breast tumors.
Stolfi RL; Sawyer RC; Martin DS
Cancer Res; 1987 Jan; 47(1):16-20. PubMed ID: 3791203
[TBL] [Abstract][Full Text] [Related]
11. A simplified method of evaluating dose-effect experiments.
LITCHFIELD JT; WILCOXON F
J Pharmacol Exp Ther; 1949 Jun; 96(2):99-113. PubMed ID: 18152921
[No Abstract] [Full Text] [Related]
12. Protein measurement with the Folin phenol reagent.
LOWRY OH; ROSEBROUGH NJ; FARR AL; RANDALL RJ
J Biol Chem; 1951 Nov; 193(1):265-75. PubMed ID: 14907713
[No Abstract] [Full Text] [Related]
13. Studies on resistance against 5-fluorouracil. I. Enzymes of the uracil pathway during development of resistance.
REICHARD P; SKOLD O; KLEIN G; REVESZ L; MAGNUSSON PH
Cancer Res; 1962 Feb; 22():235-43. PubMed ID: 14491141
[No Abstract] [Full Text] [Related]
14. Studies on fluorinated pyrimidines. IX. The degradation of 5-fluorouracil-6-C14.
MUKHERJEE KL; HEIDELBERGER C
J Biol Chem; 1960 Feb; 235():433-7. PubMed ID: 14425080
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
